Praxis Precision Medicines (PRAX) EV/EBITDA: History & Chart

Praxis Precision Medicines, Inc.(PRAX)

Biotechnology · Boston, MA

$280.14-3.42 (-1.21%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About Praxis Precision Medicines, Inc.

Praxis Precision Medicines, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating innovative treatments for central nervous system (CNS) conditions that stem from an imbalance in neuronal activity. The company's primary investigational compounds currently undergoing evaluation include: PRAX-114, an extrasynaptic-preferring positive allosteric modulator of the GABAA receptor, which is currently in Phase IIa clinical trials for addressing both major depressive disorder and perimenopausal depression. Additionally, PRAX-944, a small molecule designed to selectively inhibit T-type calcium channels, is also progressing through Phase IIa clinical trials to manage essential tremor. Beyond these, Praxis is also advancing a pipeline of other promising drug candidates, such as: PRAX-562, a persistent sodium current blocker, undergoing Phase I clinical evaluation for treating severe pediatric epilepsy and adult cephalgia (headaches). PRAX-222, an antisense oligonucleotide (ASO) aimed at individuals suffering from gain-of-function (GOF) SCN2A epilepsy. And a program targeting KCNT1 for the treatment of KCNT1 GOF epilepsy. To further its research and development efforts, Praxis maintains several strategic alliances. These include a cooperation and licensing arrangement with RogCon Inc.; a licensing deal with Purdue Neuroscience Company; a comprehensive research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and a collaborative project with The Florey Institute focused on the creation of three new antisense oligonucleotides (ASOs). Established in 2015, the company's headquarters are situated in Boston, Massachusetts.

Boston, MA

168 employees

www.praxismedicines.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Marcio Silva De'Souza

View full financials

NAME	MARKET CAP	EV/EBITDA RATIO	TTM	3Y	5Y
Praxis Precision Medicines, Inc. (PRAX)	$7.81B	N/A	N/A	N/A	N/A
Caris Life Sciences, Inc. (CAI)vs ›	$7.76B	43.23x	37.76x	37.76x	37.76x
Cytokinetics, Incorporated (CYTK)vs ›	$7.63B	N/A	135.79x	135.79x	135.79x
TG Therapeutics, Inc. (TGTX)vs ›	$7.99B	60.46x	53.51x	69.46x	69.46x
HealthEquity, Inc. (HQY)vs ›	$7.61B	17.31x	17.99x	23.37x	26.61x
Hinge Health, Inc. (HNGE)vs ›	$7.61B	75.03x	74.38x	147.51x	147.51x
Ionis Pharmaceuticals, Inc. (IONS)vs ›	$7.31B	2.21x	2.95x	2.95x	195.03x
Oscar Health, Inc. (OSCR)vs ›	$8.38B	7.27x	74.89x	49.56x	49.56x
Alkermes plc (ALKS)vs ›	$6.99B	44.98x	25.66x	15.19x	371.09x
Arrowhead Pharmaceuticals, Inc. (ARWR)vs ›	$8.67B	N/A	48.39x	48.39x	48.39x

NAME

MARKET CAP

EV/EBITDA RATIO

TTM

Praxis Precision Medicines, Inc. (PRAX)

$7.81B

N/A

Caris Life Sciences, Inc. (CAI)vs ›

$7.76B

43.23x

37.76x

Cytokinetics, Incorporated (CYTK)vs ›